You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 265 No. 20, May 22, 1991 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Reversal of Nonresponders and Postexposure Prophylaxis by Intradermal Hepatitis B Vaccination in Japanese Medical Personnel

Seiho Nagafuchi, MD; Seizaburo Kashiwagi, MD; Kenji Okada, MD; Keizo Anzai, MD; Minoru Nakamura, MD; Yasuharu Nishimura, MD; Takehiko Sasazuki, MD; Yoshiyuki Niho, MD

JAMA. 1991;265(20):2679-2683.


Abstract

Thirty-one Japanese nonresponders to subcutaneous hepatitis B vaccination and 15 medical personnel who were accidentally exposed to specimens positive for hepatitis B e antigen and were given hepatitis B immunoglobulin were intradermally immunized with 5 µg of plasma-derived hepatitis B vaccine every 2 weeks until delayed type hypersensitivity skin reaction to hepatitis B surface antigen became positive. Thirty (97%) of the 31 nonresponders developed delayed type hypersensitivity skin reactions to hepatitis B surface antigen after 2.3 ±1.2 (mean±SD) revaccinations. Twenty-nine (94%) of the 31 nonresponders had anti—hepatitis B surface antigen antibody levels greater than 10 IU/L. The immunoglobulin subclass of the antibody to hepatitis B surface antigen was mainly IgG1. After 1 year, 23 (74%) of the 31 nonresponders continued to have anti—hepatitis B surface antigen antibody levels greater than 10 IU/L. Persons accidentally exposed to specimens positive for hepatitis B e antigen developed delayed type hypersensitivity skin reactions to hepatitis B surface antigen following 3.1 ±1.1 revaccinations. None developed clinical hepatitis. There was no production of anti—hepatitis B core antigen antibody 1 year after exposure, indicating that protection was 100%. Intradermal hepatitis B vaccination is useful in reversing nonresponsiveness to hepatitis B surface antigen and for prophylaxis after exposure.

(JAMA. 1991;265:2679-2683)



Author Affiliations

From the First Department of Internal Medicine (Drs Nagafuchi, Anzai, Nakamura, and Niho), the Department of General Medicine (Dr Kashiwagi), and the Department of Pediatrics (Dr Okada), Faculty of Medicine, and the Department of Genetics, Medical Institute of Bioregulation (Drs Nishimura and Sasazuki), Kyushu University, Fukuoka, Japan.


Footnotes

Reprint requests to the First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, 812 Japan (Dr Nagafuchi).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hyporesponsiveness to intradermal administration of hepatitis B vaccine in insulin dependent diabetes mellitus
Volti et al.
Arch. Dis. Child. 1998;78:54-57.
ABSTRACT | FULL TEXT  

Immunogenicity of Hepatitis B Vaccines
Needles
JAMA 1994;272:201-202.
ABSTRACT  

INTRADERMAL HEPATITIS B VACCINATION
JWatch General 1991;1991:5-5.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.